222 results on '"Tabberer, Maggie"'
Search Results
2. Selective androgen receptor modulation for muscle weakness in chronic obstructive pulmonary disease: a randomised control trial
3. Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study
4. Defining Chronic Mucus Hypersecretion Using the CAT in the SPIROMICS Cohort
5. Patient experience of moderate asthma attacks: qualitative research in the USA and Germany
6. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial
7. Measuring respiratory symptoms in moderate/severe asthma: evaluation of a respiratory symptom tool, the E-RS®: COPD in asthma populations
8. Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study
9. Improved Decision-Making Confidence Using Item-Based Pharmacometric Model: Illustration with a Phase II Placebo-Controlled Trial
10. Correction to: Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study
11. Assessment of the efficacy and safety of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler versus a multi-dose inhaler in patients with chronic obstructive pulmonary disease
12. Assessing asthma symptoms in children: qualitative research supporting the development of the Pediatric Asthma Diary—Child (PAD-C) and Pediatric Asthma Diary—Observer (PAD-O).
13. Assessment of the efficacy and safety of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler and a multi-dose inhaler in patients with asthma
14. Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life
15. Additional file 1 of Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study
16. Selective androgen receptor modulation for muscle weakness in chronic obstructive pulmonary disease: a randomised control trial
17. Once-Daily Triple Therapy in Patients with Advanced COPD: Healthcare Resource Utilization Data and Associated Costs from the FULFIL Trial
18. Reply to Suissa and Ariel: The FULFIL Trial
19. Reply: “FULFIL an Unmet Need in Chronic Obstructive Pulmonary Disease” and “Triple Therapy in Chronic Obstructive Pulmonary Disease”
20. Defining Chronic Mucus Hypersecretion Using the CAT in the SPIROMICS Cohort
21. Additional file 2 of Patient experience of moderate asthma attacks: qualitative research in the USA and Germany
22. Additional file 1 of Patient experience of moderate asthma attacks: qualitative research in the USA and Germany
23. Higher COPD Assessment Test Score Associated With Greater Exacerbations Risk: A Post Hoc Analysis of the IMPACT Trial
24. Additional file 1 of Measuring respiratory symptoms in moderate/severe asthma: evaluation of a respiratory symptom tool, the E-RS®: COPD in asthma populations
25. Nemiralisib in Patients with an Acute Exacerbation of COPD: Placebo-Controlled, Dose-Ranging Study
26. INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice
27. CAPTAIN STUDY: ASSOCIATION OF MODERATE AND SEVERE ASTHMA EXACERBATIONS WITH LUNG FUNCTION AND PATIENT-REPORTED OUTCOMES IN A LARGE RANDOMIZED PHASE III CLINICAL TRIAL
28. Once-Daily Umeclidinium/Vilanterol 125/25 μg Therapy in COPD: A Randomized, Controlled Study
29. Mepolizumab Improves Health Related Quality of Life for Patients with Chronic Rhinosinusitis with Nasal Polyps: Data from the SYNAPSE study
30. Mepolizumab reduces disease symptoms for Patients with Chronic Rhinosinusitis with Nasal Polyps: Data from the SYNAPSE study
31. Validity and responsiveness of the Daily- and Clinical visit-PROactive Physical Activity in COPD (D-PPAC and C-PPAC) instruments
32. PREVALENCE OF ASTHMA CONTROL AND THE ASSOCIATED DISEASE BURDEN IN US PATIENTS WITH ASTHMA TREATED WITH A FIXED-DOSE COMBINATION OF INHALED CORTICOSTEROID AND LONG-ACTING BETA2-AGONIST
33. Tests of the Responsiveness of the COPD Assessment Test Following Acute Exacerbation and Pulmonary Rehabilitation
34. INTREPID study: Once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol vs multiple-inhaler triple therapy; sub-analysis by prior medication strata
35. Clinical Development and Research Applications of the Chronic Obstructive Pulmonary Disease Assessment Test
36. Once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI in inadequately controlled asthma: the CAPTAIN study
37. Assessment of the COPD Assessment Test Within U.S. Primary Care
38. Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol in usual practice: the COPD INTREPID study design
39. Prediction of muscle weakness in COPD: results from modelling using the ERICA cohort
40. Preventing clinically important deterioration with single-inhaler triple therapy in COPD
41. Interpreting patient-reported outcomes from clinical trials in COPD: a discussion
42. Single inhaler triple therapy in patients with COPD: patient-reported dyspnoea and health status from the IMPACT Trial
43. Late Breaking Abstract - Overlap of SGRQ and CAT-defined chronic mucus hypersecretion in the SPIROMICS cohort: implications for digital health
44. Late Breaking Abstract - Analysis of the InforMing the PAthway of COPD Treatment (IMPACT) study in the subgroup of patients taking triple therapy at screening
45. How are recovery and recurrence of COPD exacerbations defined in observational studies? A systematic review
46. Single inhaler triple therapy in patients with COPD: response rates in health-related quality of life in the IMPACT Trial
47. Systematic review of COPD re-exacerbation and exacerbation treatment failure definitions used in randomised controlled trials (RCTs)
48. Effect of the CXCR2 antagonist danirixin on symptoms and health status in COPD
49. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD
50. Reply to Morice and Hart: Increased Propensity for Pneumonia with Fluticasone in Chronic Obstructive Pulmonary Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.